Inpharma 1309 - 13 Oct 2001

■ BBR 2778* shows efficacy in the treatment ofrelapsed, aggressive non-Hodgkin’s lymphoma (NHL),according to a preliminary analysis of study datapresented at the annual meeting of the GermanSociety of Hematology, held recently in Mannheim,Germany. Data were analysed from 27 patients withNHL who participated in the open-label studyconducted in Germany and France.** Patients weretreated with ≤ 6 cycles of BBR 2778, administeredintravenously at a dose of 85 mg/m2 once weekly for 3weeks. Three patients had a complete response and 3had a partial response. BBR 2778 was generally welltolerated, with the most common adverse effect beingneutropenia.* Novuspharma; phase II for non-Hodgkin’s lymphoma** Most patients had advanced disease and had experiencedrelapse after prior chemotherapy.

Novuspharma SpA. Novuspharma announces positive phase II results for BBR2778 in non-Hodgkin’s lymphoma. Media Release : [2 pages], 1 Oct 2001.Available from: URL: http://www.novuspharma.com 800876260

1

Inpharma 13 Oct 2001 No. 13091173-8324/10/1309-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved